Stifel says its survey of 100 providers of Align's Invisalign showed that only 8% of practices would switch to a competing product that was less advanced but 30% cheaper. The firm says that the survey results were favorable to Align and show that the company is well-positioned to withstand additional competition. It keeps an $82 price target and Buy rating on the shares.
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here